Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Transplant ; 7(5): 1181-4, 2007 May.
Article in English | MEDLINE | ID: mdl-17359511

ABSTRACT

The long-term outcome of kidneys transplanted from blood group A(2) live donors into blood group O or B candidates is not known. From 1986 through 2006, we transplanted eight blood group O patients and one blood group B patient with kidneys from blood group A(2) live donors. Immunosuppression was no different for these patients than for ABO-compatible recipients. All patients received methylprednisolone, cyclosporine or tacrolimus and azathioprine or mycophenolate mofetil with or without antibody induction (monoclonal or polyclonal). Of the nine live-donor A(2) to O and B transplants performed, seven grafts remain functioning. One of those seven was lost to follow-up at 9.2 years with a functioning kidney. Of the remaining six patients, length of follow-up is 10.4, 6.5, 5.3, 4, 2.1 and 1 years. Of the two patients who lost their grafts, one died with a functioning graft (DWFG) at 8.8 years and one lost his graft at 13.2 years due to noncompliance with immunosuppression. These data show that good long-term graft survival can be expected in live-donor A(2) to O and B transplantation despite some of those patients experiencing the type of clinical problems seen with ABO-compatible transplants.


Subject(s)
ABO Blood-Group System/immunology , Graft Survival/physiology , Kidney Transplantation/immunology , Kidney Transplantation/physiology , Living Donors , Azathioprine/therapeutic use , Blood Grouping and Crossmatching , Cyclosporine/therapeutic use , Follow-Up Studies , Graft Rejection/immunology , Graft Rejection/prevention & control , Graft Survival/immunology , Humans , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/methods , Methylprednisolone/therapeutic use , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Tacrolimus/therapeutic use , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL